As soon as your results follow, Oryzon can become one of the positive surprises for next year in the Spanish equity market. Because it still presents a margin of improvement in its business accounts that is worthy of value by financial analysts. Where it has a potential for revaluation that can be very powerful if the expectations created in the stock market are met, as the main characteristic in this class of securities that are listed on the national continuous market.
This listed company was founded in 2000 in Barcelona, and Oryzon is a biopharmaceutical company clinical phase European leader in Epigenetics. Where it stands out for having one of the strongest portfolios in the sector. Although it is a proposal to make our savings profitable, which is driven by strong impulses, in one sense or another. Where the same you can earn a 20% profitability in a very short space of time than leaving the same or even more percentage in this period of permanence. It is reserved for small and medium investors who know how to operate with these securities and who also present a certain learning in their movements in the equity markets.
While on the other hand, it is immersed in a sector, that of biopharmaceutical companies, which is characterized by its high volatility in the conformation of its prices. As soon as it can go up 5% that the next day the same amount is left in the percentage. They are values that are very conducive to the operations of trading since its margins are very wide from any kind of investment strategy. So that in this way, you can make the money profitable in a broader way than through other securities that are listed in the selective index of Spanish equities, the Ibex 35.
Oryzon trades close to 2 euros
At the moment, the company's shares are trading at just over two euros and after an annual revaluation that is established in 11%. Although with many differences in each of the months since it is a listed company that is driven by expectations rather than realities. As one of its main differences with respect to the first final values that are integrated in the Ibex 35. Where any error can lead to appreciations of around 5% or even higher percentages, as has happened in recent years. years.
In either case, it is a market value that has its target weight established in a little more than 3 euros per share. In other words, it has a potential revaluation at this time of almost 15%. From this point of view, there is no doubt that it is a proposal in national equities that invites positions to be taken to make the savings profitable in a short period of time. Despite the many ups and downs it has been suffering in the financial markets.
Nature of the company
This company belongs to a very innovative sector and little explored by our equities. If not, on the contrary, it is in a segment that is conducive to performing operations of speculative character to get a capital to settle the movements in the stock market. Because indeed, and so that you have a little clearer ideas from now on, it is convenient for you to know what is the professional activity that this listed company has been developing. So that you can make a more informed decision and in this way avoid falling into some kind of mistakes that can cost your personal interests dearly. And that is after all one of your priority objectives now.
Well, Oryzon Genomics, SA, a clinical phase biopharmaceutical company focused on epigenetics for the development of therapies in diseases with important unresolved medical needs. It is, in short, a very new sector and one of which there are very few representatives in the national equity markets. Even from secondary markets such as the Alternative Stock Market (MAB) that are characterized by their high liquidity. Where you can have certain problems adjusting the entry and exit prices in the value.
Value characteristics
A listed company, as in this case, stands out above all because its contracting volume is very small, as move every day very few titles and that in a certain way it can harm you in the movements that you are going to perform from now on. Among other reasons because you can not always make purchases at the time you want. As one of the signs of identity in this class of new-appearing proposals that are not the most desired titles to create a stable savings exchange for the medium and long term. And in some cases, not even in the short term due to the risks that you can take on in this kind of trading on the stock market.
While on the other hand, you cannot forget that this specific value is very prone to carry out operations in a very few days, even within the same trading session. To get capital gains, the faster the better for your investment strategies. Certainly not to hold positions for many months or even years. For this you have other values that are more advisable from any investment perspective. For example, those represented through the members of the selective index of national equities, the Ibex 35. With options such as Mapfre, Endesa, BBVA or ACS.
Risks in operations
As we have said before, one of the dangers when taking positions in this special security is the risk that this type of operation entails. In the sense that either you can stay hooked or on the contrary that you directly lose many euros along the way. Because one of the keys to staying in value is knowing how to exit at the right time and without extending positions under any circumstances. Indeed, you have to be very aware of its evolution in the equity markets before what may happen in the following trading sessions.
On the other hand, it must also be emphasized that this value is rarely part of the investment portfolios prepared by managers, both nationally and outside our borders. By being in a certain way a little unprotected from the recommendations of the different financial intermediaries. That is, you will have more problems to develop any investment strategy and that may cause you some other inconvenience in operations. From the approach that you have decided to make profitable the capital destined for these movements in the stock market.
Through operations that provide little security, as happens with the securities that are part of the Ibex 35. From this point of view, you must act with much more caution than in these so that you do not have negative surprises that could make you decrease the balance of your savings account. Only from more or less reasonable margins for your interests in the financial markets. Because at the end of the day what it is about is to make money profitable in the absence of alternatives in fixed income. Where interests barely exceed 0,3%, as in the case of fixed-term bank deposits. Therefore, a lot of diligence when opening positions because the risk is always latent at any time. More than you can believe from the beginning and that can not lead you to meet the objectives.
Increase your income by 42%
Revenues at the end of the third quarter of 2019 for this company amounted to a total of 7,4 million euros, which is 42,3% more than in the third quarter of 2018. The company has recognized income relating to work carried out for the fixed assets itself of 7,4 million euros. In the investments in R&D is 8,2 million euros, of which 7,4 million euros correspond to development and 0,8 million euros to research that have been taken directly to expenses for the period, representing an increase of 51,9% in investment capacity compared to the third quarter of 2018. From the approach you have decided to make the capital earmarked for these movements on the stock market profitable.
The net result of its accounting balance is 2,7 million euros of loss is in accordance with the specificity of the biotechnology business model, in the development phase in which the company is, with a period of maturity of its long-term products, and without recurrences from an income perspective. Where at the end of the third quarter, cash and available financial investments amount to 39,1 million euros. While on the other hand, it has carried out a capital increase equivalent to 20,0 million euros, capturing the interest of international investors.